Regeneron (NASDAQ: REGN) reported Q3 EPS of $3.99, $0.14 better than the analyst estimate of $3.85. Revenue for the quarter came in at $1.5 billion versus the consensus estimate of $1.46 billion.

• Third quarter 2017 EYLEA® (aflibercept) Injection U.S. net sales increased 12% to $953 million versus third quarter 2016
• Third quarter 2017 EYLEA global net sales(1) increased 15% to $1.52 billion versus third quarter 2016
• Third quarter 2017 GAAP net income per diluted share increased 46% to $3.32 versus third quarter 2016. Third quarter 2017 non-GAAP net income per diluted share increased 27% to $3.99 versus third quarter 2016.
• Phase 3 EYLEA PANORAMA study for the treatment of diabetic retinopathy is fully enrolled with U.S. regulatory submission expected in 2018
• Appellate court ordered a new trial and vacated permanent injunction in U.S. Praluent® patent case

For earnings history and earnings-related data on Regeneron (REGN) click here.